The Evolving Role of Immunotherapy in Metastatic Non–Small Cell Lung Cancer - Episode 9

The Evolving Role of Immunotherapy in Metastatic Non–Small Cell Lung Cancer

This publication reviews the role of single-agent and dual immunotherapy for the treatment of metastatic non-small-cell lung cancer, recapping key insights from a scientific interchange & workshop.

EP. 1: Dr. Giaccone on Treatment Options in NSCLC
EP. 2: Dr. Rizvi on Biomarkers of Response to Immunotherapy in NSCLC
EP. 3: Dr. West on the Use of Nivolumab/Ipilimumab in Metastatic NSCLC
EP. 4: Dr. Gandara on the Benefit of Nivolumab/Ipilimumab Plus Chemo in Metastatic NSCLC
EP. 5: Dr. Rizvi on the Implications of the CheckMate-227 Trial With Nivolumab/Ipilimumab in NSCLC
EP. 6: Dr. Wozniak on Optimizing the Use of Immunotherapy in NSCLC
EP. 7: Dr. Raez on the Impact of PD-L1 Status on Immunotherapy Outcomes in NSCLC
EP. 8: Dr. Garon on Immunotherapy Treatment Considerations in NSCLC
Now Viewing
EP. 9: The Evolving Role of Immunotherapy in Metastatic Non–Small Cell Lung Cancer